Another positive is we have made a discovery that will allow us to significantly speed up the downstream clinical trials which we probably wouldn’t have found if the engineering batch had been manufactured more efficiently.
Hi@Davisite , I assume that this discovery will be talked about in detail in the new strategy ?
I am a bit confused by this.
Did you mean that you wouldn't have found this discovery if the engineering batch had been manufactured LESS efficiently , instead of more ?
Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-223
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.045(2.73%) |
Mkt cap ! $273.5M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.66 | $1.61 | $159.4K | 98.03K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5684 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |